Targeting Type 2 inflammation: treating the common denominator

Sponsored by Sanofi-aventis Australia Pty Ltd

Type 2 inflammation is emerging as a unifying feature of multiple inflammatory diseases, including asthma. As part of the ADVENT Advances in Type 2 Inflammatory Diseases medical education series run by Sanofi Genzyme, allergy specialist and immunologist Professor Connie Katelaris talks about how Type 2 inflammatory pathway-focused treatments have major implications in the management of ...

Already a member?

Login to keep reading.

© 2021 the limbic